A novel alkyl phosphocholine-dinitroaniline hybrid molecule exhibits biological activity in vitro against Leishmania amazonensis

Experimental Parasitology

Volumn 135, Issue 1, 2013, Pages 153-165

  Godinho, Joseane Lima Prado ^a   Georgikopoulou, Kalliopi ^b   Calogeropoulou, Theodora ^b   de Souza, Wanderley ^a,c,d   Rodrigues, Juliany Cola Fernandes ^a,c,d  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTE OF BIOLOGY   (Greece)

^c INSTITUTO NACIONAL DE METROLOGIA   (Brazil)

^d Centro Nacional de Ressonância Magnética Nuclear Jiri Jonas Instituto de Bioquímica Médica Leopoldo de Meis Instituto Nacional de Ciência e Tecnologia de Biologia Estrutural e Bioimagem   (Brazil)

Author keywords

Alkyl phospholipid analogues; Chemotherapy; Dinitroanilines; Hybrid molecule; Leishmania; Ultrastructure

Indexed keywords

[11 [[(2,6 DINITRO 4 TRIFLUOROMETHYL)PHENYL]BUTYLAMINO](UNDECYLPHOSPINYLOXY)ETHYL] N,N,N TRIMETHYLAMMONIUM; ANTILEISHMANIAL AGENT; TUBULIN; UNCLASSIFIED DRUG;

AMASTIGOTE; ANIMAL CELL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL CYCLE ARREST; CELL SHAPE; CELL ULTRASTRUCTURE; CONTROLLED STUDY; CYTOSKELETON; DRUG STRUCTURE; ENDOPLASMIC RETICULUM; FLAGELLUM; FLUORESCENCE MICROSCOPY; FLUOROMETRY; GOLGI COMPLEX; IC 50; LEISHMANIA; LIPID STORAGE; MEMBRANE DAMAGE; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE; SCANNING ELECTRON MICROSCOPY; TRANSMISSION ELECTRON MICROSCOPY;

ALKYL PHOSPHOLIPID ANALOGUES; CHEMOTHERAPY; DINITROANILINES; HYBRID MOLECULE; LEISHMANIA; ULTRASTRUCTURE;

ANILINE COMPOUNDS; ANIMALS; ANTIPROTOZOAL AGENTS; CELL CYCLE CHECKPOINTS; CELL MEMBRANE; CYTOSKELETON; FLOW CYTOMETRY; HISTOCYTOCHEMISTRY; HUMANS; INCLUSION BODIES; INHIBITORY CONCENTRATION 50; LEISHMANIA MEXICANA; LEISHMANIASIS, DIFFUSE CUTANEOUS; MACROPHAGES, PERITONEAL; MICE; MICROSCOPY, ELECTRON, SCANNING; MICROSCOPY, ELECTRON, TRANSMISSION; MICROSCOPY, FLUORESCENCE; MICROSCOPY, INTERFERENCE; PHOSPHORYLCHOLINE; TRIFLURALIN;

EID: 84882791924     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2013.06.015     Document Type: Article

References (31)

1. Alvar J., Vélez I.D., Bern C., Herrero M., Desjeux P., Cano J., Jannin J., den Boer M. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 2012, 7:e35671.
2. Angermüller S., Fahimi H.D. Imidazole-buffered osmium tetroxide: an excellent stain for visualization of lipids in transmission electron microscopy. Histochem. J. 1982, 14:823-835.
3. Barratt G., Saint-Pierre-Chazalet M., Loiseau P.M. Cellular transport and lipid interactions of miltefosine. Curr. Drug Metab. 2009, 10:247-255.
4. Chan M.M., Fong D. Inhibition of leishmanias but not host macrophages by the antitubulin herbicide trifluralin. Science 1990, 249:924-926.
5. Dowlati Y. Cutaneous leishmaniasis: clinical aspect. Clin. Dermatol. 1996, 14:425-431.
6. Havens C.G., Bryant N., Asher L., Lamoreaux L., Perfetto S., Brendle J.J., Werbovetz K.A. Cellular effects of leishmanial tubulin inhibitors on L. donovani. Mol. Biochem. Parasitol. 2000, 110:223-226.
7. Henriques C., Moreira T.L.B., Maia-Brigagão C., Henriques-Pons A., Carvalho T.M.U., de Souza W. Tetrazolium salt based methods for high-throughput evaluation of anti-parasite chemotherapy. Anal. Methods 2011, 3:2148.
8. Langhans M., Niemes S., Pimpl P., Robinson D.G. Oryzalin bodies: in addition to its anti-microtubule properties, the dinitroaniline herbicide oryzalin causes nodulation of the endoplasmic reticulum. Protoplasma 2009, 236:73-84.
9. Lira R., Contreras L.M., Santa-Rita R.M., Urbina J.A. Mechanism of action of anti-proliferative lysophospholipid analogues against the protozoan parasite Trypanosoma cruzi: potentiation of in vitro activity by the sterol biosynthesis inhibitor ketoconazole. J. Antimicrob. Chemother. 2001, 47:537-546.
10. Lux H., Heise N., Klenner T., Hart D., Opperdoes F.R. Ether-Lipid (alkyl-phospholipid) metabolism and the mechanism of action of the ether-lipid analogues in Leishmania. Mol. Biochem. Parasitol. 2000, 111:1-14.
11. Marsden P.D., Jones T.C. Clinical manifestations, diagnosis, and treatment of leishmaniasis. Human Parasitic Diseases 1985, 183-198. Leishmaniasis, Elsevier Science, New York. K.P. Chang, R.S. Bray (Eds.).
12. Martin C.O., Comly M.E., Blanchette-Mackie E.J., Pentchev P.G., Pagano R.E. Cholesterol deprivation affects fluorescence properties of a ceramide analog at the Golgi apparatus of living cells. Proc. Natl. Acad. Sci. USA 1993, 90:1661-1665.
13. Martin M.B., Grimley J.S., Lewis J.C., Heath H.T., Bailey B.N., Kendrick H., Yardley V., Caldera A., Lira R., Urbina J.A., Moreno S.N., Docampo R., Croft S.L., Oldfield E. Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy. J. Med. Chem. 2001, 44:909-916.
14. Morejohn L.C., Bureau T.E., Molè-Bajer J., Bajer A.S., Fosket D.E. Oryzalin, a dinitroaniline herbicide, binds to plant tubulin and inhibits microtubule polymerization in vitro. Planta 1987, 172:252-264.
15. Morgan R.E., Werbovetz K.A. Selective lead compounds against kinetoplastid tubulin. Drug Targets in Kinetoplastid Parasites 2008, 33-47. Springer, New York, (625). H.K. Majunder (Ed.).
16. Oliveira L.F., Schubach A.O., Martins M.M., Passos S.L., Oliveira R.V., Marzochi M.C., Andrade C.A. Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World. Acta Trop. 2011, 118:87-96.
17. Palmié-Peixoto I., Rocha M.R., Urbina J.A., de Souza W., Einecker-Lamas M., Motta M.C.M. Effects of sterol biosynthesis inhibitors on endosymbiont-bearing trypanosomatids. FEMS Microbiol. Lett. 2006, 255:33-42.
18. Paris C., Loiseau P.M., Bories C., Bréard J. Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes. Antimicrob. Agents Chemother. 2004, 48:852-859.
19. Rakotomanga M., Loiseau P.M., Saint-Pierre-Chazalet M. Hexadecylphosphocoline interaction with lipid monolayers. Biochim. Biophys. Acta 2004, 1661:212-218.
20. Rodrigues J.C.F., de Souza W. Ultrastrutural alterations in organelles of parasitic protozoan induced by different classes of metabolic inhibitors. Curr. Pharm. Des. 2008, 14:925-938.
21. Rodrigues C.O., Catisti R., Uyemura S.A., Vercesi A.E., Lira R., Rodriguez C., Urbina J.A., Docampo R. The sterol composition of Trypanosoma cruzi changes after growth in different culture media and results in different sensitivity to digitonin-permeabilization. J. Eukaryot. Microbiol. 2001, 48:588-594.
22. Rodrigues J.C.F., Bernardes C.F., Visbal G., Urbina J.A., Vercesi A.E., de Souza W. Sterol methenyl transferase inhibitors alter the ultrastructure and function of the Leishmania amazonensis mitochondrion leading to potent growth inhibition. Protist 2007, 158:447-456.
23. Rodrigues J.C.F., Concepcion J.L., Rodrigues C., Caldera A., Urbina J.A., de Souza W. In vitro activities of ER-119884 and E5700, two potent squalene synthase inhibitors, against Leishmania amazonensis: antiproliferative, biochemical and ultraestructural effects. Antimicrob. Agents Chemother. 2008, 52:4098-4114.
24. Santa-Rita R.M., Barbosa H.S., Meirelles M.N., de Castro S.L. Effect of the alkyl-lysophospholipids on the proliferation and differentiation of Trypanosoma cruzi. Acta Trop. 2000, 75:219-228.
25. Santa-Rita R.M., Henriques-Pons A., Barbosa H.S., de Castro S.L. Effect of the lysophospholipid analogues edelfosine, ilmofosine and miltefosine against Leishmania amazonensis. J. Antimicrob. Chemother. 2004, 54:704-710.
26. +-ATPase and protein kinase C are targets to 1-O-hexadecylphosphocoline (miltefosine) in Trypanosoma cruzi. Arch. Biochem. Biophys. 2009, 481:65-71.
27. Sundar S., Jha T.K., Thakur C.P., Engel J., Sindermann H., Fischer C., Junge K., Bryceson A., Berman J. Oral miltefosine for Indian visceral leishmaniasis. N. Engl. J. Med. 2002, 28:1739-1746.
28. Urbina J.A. Mechanisms of action of lysophospholipid analogues against trypanosomatid parasites. Trans. R. Soc. Trop. Med. Hyg. 2006, 100:S9-S16.
29. van Blitterswijk W.J., Verheij M. Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects. Curr. Pharm. Des. 2008, 14:2061-2074.
30. Walsh J.J., Bell A. Hybrid drugs for malaria. Curr. Pharm. Des. 2009, 15:2970-2985.
31. Walther T.C., Farese R.V. The life of lipid droplets. Biochim. Biophys. Acta 2009, 1791:459-466.